Simcha Therapeutics

Simcha Therapeutics is a biotechnology company located in New Haven, Connecticut, dedicated to developing biologics that modulate cytokine pathways. The company uses directed evolution technology to design novel cytokines, aiming to unlock the precision and functionality of the immune system. Its lead asset, ST-067, activates the IL-18 receptor, triggering potent inflammatory signaling in anti-tumor immune cells within both the adaptive and innate branches of the immune system.